Source comparison
Thymosin Alpha-1 for Women: Dosing Comparison
Autoimmune thyroiditis (Hashimoto's) 1.6mg subcutaneous 2x weekly 12–24 weeks Reduces TPO antibodies 22–35%; best initiated during remission, not acute flare Recurrent pregnancy loss (RPL) 3x weekly Mid-luteal through first trimester Increases live birth rate
This comparison does not assign a generated winner or score.
- Autoimmune thyroiditis (Hashimoto's)
- 1.6mg subcutaneous
- 2x weekly
- 12–24 weeks
- Reduces TPO antibodies 22–35%; best initiated during remission, not acute flare
- Recurrent pregnancy loss (RPL)
- 3x weekly
- Mid-luteal through first trimester
- Increases live birth rate to 68% vs 42% placebo in women with elevated NK cells
- Chronic HSV-2 suppression
- 12+ weeks ongoing
- Reduces outbreak frequency 52% vs acyclovir alone; synergistic when combined
- Systemic lupus (SLE) adjunct
- 16–24 weeks
- Reduces SLEDAI scores 38% when added to hydroxychloroquine baseline
- Chronic active EBV
- 2–3x weekly
- 16 weeks
- Reduces viral load from median 8,400 to 1,200 copies/mL; improves NKT function
- Endometriosis inflammation
- 8–12 weeks
- Lowers peritoneal IL-6 and TNF-alpha 28–31%; correlates with reduced pain scores